涉及纳米医学的临床试验中的伦理问题。
Ethical issues in clinical trials involving nanomedicine.
作者信息
Resnik David B, Tinkle Sally S
机构信息
National Institute of Environmental Health Sciences, National Institutes of Health, Box 12233, Mail Drop NH06, Research Triangle Park, NC 27709, United States.
出版信息
Contemp Clin Trials. 2007 Jul;28(4):433-41. doi: 10.1016/j.cct.2006.11.001. Epub 2006 Nov 17.
Abstract
Nanomedicine shows tremendous promise for improving medical diagnosis, treatment, and prevention, but it also raises a variety of ethical concerns. Because of the paucity of data on the physicochemical properties of nanoscale materials in biological systems, clinical trials of nanomedicine products present some unique challenges related to risk minimization, management and communication involving human subjects. Although these clinical trials do not raise any truly novel ethical issues, the rapid development of nanotechnology and its potentially profound social and environmental impacts, add a sense of urgency to the problems that arise.
摘要
纳米医学在改善医学诊断、治疗和预防方面显示出巨大的前景，但也引发了各种伦理问题。由于生物系统中纳米级材料的物理化学性质的数据匮乏，纳米医学产品的临床试验在涉及人类受试者的风险最小化、管理和沟通方面存在一些独特的挑战。尽管这些临床试验没有引发任何真正新颖的伦理问题，但纳米技术的快速发展及其潜在的深远社会和环境影响，给所出现的问题增添了紧迫感。
相似文献
1
Ethical issues in clinical trials involving nanomedicine.
Contemp Clin Trials. 2007 Jul;28(4):433-41. doi: 10.1016/j.cct.2006.11.001. Epub 2006 Nov 17.
2
Responsible conduct in nanomedicine research: environmental concerns beyond the common rule.
J Law Med Ethics. 2012 Winter;40(4):848-55. doi: 10.1111/j.1748-720X.2012.00713.x.
3
Prudent precaution in clinical trials of nanomedicines.
J Law Med Ethics. 2012 Winter;40(4):831-40. doi: 10.1111/j.1748-720X.2012.00711.x.
4
Ethics in nanomedicine.
Nanomedicine (Lond). 2007 Jun;2(3):345-50. doi: 10.2217/17435889.2.3.345.
5
Naming it 'nano': Expert views on 'nano' terminology in informed consent forms of first-in-human nanomedicine trials.
Nanomedicine (Lond). 2016 Apr;11(8):933-40. doi: 10.2217/nnm-2015-0003. Epub 2016 Mar 16.
6
A portrait of nanomedicine and its bioethical implications.
J Law Med Ethics. 2012 Winter;40(4):763-79. doi: 10.1111/j.1748-720X.2012.00705.x.
7
Managing the "known unknowns": theranostic cancer nanomedicine and informed consent.
Methods Mol Biol. 2011;726:413-29. doi: 10.1007/978-1-61779-052-2_26.
8
Consent in clinical trials: what do patients know?
Contemp Clin Trials. 2010 Sep;31(5):443-6. doi: 10.1016/j.cct.2010.05.004. Epub 2010 May 10.
9
[Different opinions when it comes to research ethics issues concerning patients with dementia. A questionnaire study among members of research ethics committees].
Lakartidningen. 2004 May 13;101(20):1810-2.
10
Beyond human subjects: risk, ethics, and clinical development of nanomedicines.
J Law Med Ethics. 2012 Winter;40(4):841-7. doi: 10.1111/j.1748-720X.2012.00712.x.
引用本文的文献
1
The evolution of integrated magnetic hyperthermia and chemodynamic therapy for combating cancer: a comprehensive viewpoint.
Nanoscale Adv. 2025 Jul 23. doi: 10.1039/d4na01004c.
2
Advances in nanotechnology for colorectal cancer: a smart targeting and theranostics approach.
Med Oncol. 2025 Jul 18;42(8):346. doi: 10.1007/s12032-025-02910-2.
3
From Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment.
Breast Cancer (Dove Med Press). 2025 Jan 21;17:27-51. doi: 10.2147/BCTT.S501448. eCollection 2025.
4
Nano Revolution: "Tiny tech, big impact: How nanotechnology is driving SDGs progress".
Heliyon. 2024 May 16;10(10):e31393. doi: 10.1016/j.heliyon.2024.e31393. eCollection 2024 May 30.
5
Advances in Nanotechnology for Enhancing the Solubility and Bioavailability of Poorly Soluble Drugs.
Drug Des Devel Ther. 2024 May 1;18:1469-1495. doi: 10.2147/DDDT.S447496. eCollection 2024.
6
Wound healing strategies based on nanoparticles incorporated in hydrogel wound patches.
RSC Adv. 2023 Jul 17;13(31):21345-21364. doi: 10.1039/d3ra03477a. eCollection 2023 Jul 12.
7
The Emerging Role of Ultrasonic Nanotechnology for Diagnosing and Treatment of Diseases.
Front Med (Lausanne). 2022 Feb 22;9:814986. doi: 10.3389/fmed.2022.814986. eCollection 2022.
8
Development of Pharmaceutical Nanomedicines: From the Bench to the Market.
Pharmaceutics. 2022 Jan 3;14(1):106. doi: 10.3390/pharmaceutics14010106.
9
Thermoresponsive Chitosan-Grafted-Poly(-vinylcaprolactam) Microgels via Ionotropic Gelation for Oncological Applications.
Pharmaceutics. 2021 Oct 11;13(10):1654. doi: 10.3390/pharmaceutics13101654.
10
Organ-on-a-chip platforms for accelerating the evaluation of nanomedicine.
Bioact Mater. 2020 Oct 12;6(4):1012-1027. doi: 10.1016/j.bioactmat.2020.09.022. eCollection 2021 Apr.
本文引用的文献
1
Protecting third parties in human subjects research.
IRB. 2006 Jul-Aug;28(4):1-7.
2
Strategies to minimize risks and exploitation in phase one trials on healthy subjects.
Am J Bioeth. 2006 May-Jun;6(3):W1-13. doi: 10.1080/15265160600686281.
3
TGN1412: time to change the paradigm for the testing of new pharmaceuticals.
Altern Lab Anim. 2006 May;34(2):225-39. doi: 10.1177/026119290603400204.
4
Injury to research volunteers--the clinical-research nightmare.
N Engl J Med. 2006 May 4;354(18):1869-71. doi: 10.1056/NEJMp068082.
5
How the US drug safety system should be changed.
JAMA. 2006 May 3;295(17):2072-5. doi: 10.1001/jama.295.17.2072.
6
First experimental demonstration of the multipotential carcinogenic effects of aspartame administered in the feed to Sprague-Dawley rats.
Environ Health Perspect. 2006 Mar;114(3):379-85. doi: 10.1289/ehp.8711.
7
Materials and biology. Nanotechnology takes aim at cancer.
Science. 2005 Nov 18;310(5751):1132-4. doi: 10.1126/science.310.5751.1132.
8
Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells.
Environ Health Perspect. 2005 Nov;113(11):1555-60. doi: 10.1289/ehp.8006.
9
Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit.
JAMA. 2005 Aug 17;294(7):826-32. doi: 10.1001/jama.294.7.826.
10
Animal models and their limitations: on the problem of high-to-low dose extrapolations following inhalation exposures.
Exp Toxicol Pathol. 2005 Jul;57 Suppl 1:143-6. doi: 10.1016/j.etp.2005.05.016.
Zotero 插件